Who is sponsoring NCT04526990?

NCT04526990 is sponsored by CanSino Biologics Inc..

What drugs are being tested in NCT04526990?

Interventions in NCT04526990: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo.

Is NCT04526990 still recruiting?

NCT04526990 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT04526990

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed Phase 3 Last updated 15 June 2023

What this trial tests

Phase 3 trial testing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in COVID-19 in 44,247 participants. Completed in 21 October 2022.

Timeline

15 September 2020

Primary endpoint
7 August 2021

21 October 2022

Quick facts

Lead sponsor	CanSino Biologics Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	44,247
Start date	15 September 2020
Primary completion	7 August 2021
Estimated completion	21 October 2022
Sites	74 locations across Pakistan, Russia, Chile, Mexico, Argentina

Drugs / interventions tested

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

CanSino Biologics Inc. — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Viral targets for vaccines against COVID-19.
Dai L, Gao GF. · · 2021 · cited 836× · PMID 33340022 · DOI 10.1038/s41577-020-00480-0
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.
Tregoning JS, Flight KE, Higham SL, Wang Z, et al · · 2021 · cited 827× · PMID 34373623 · DOI 10.1038/s41577-021-00592-1
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, et al · · 2021 · cited 507× · PMID 33619260 · DOI 10.1038/s41541-021-00292-w
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
Poland GA, Ovsyannikova IG, Kennedy RB. · · 2020 · cited 463× · PMID 33065034 · DOI 10.1016/s0140-6736(20)32137-1
COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention.
Sharma A, Ahmad Farouk I, Lal SK. · · 2021 · cited 345× · PMID 33572857 · DOI 10.3390/v13020202
COVID-19 vaccine development: milestones, lessons and prospects.
Li M, Wang H, Tian L, Pang Z, et al · · 2022 · cited 298× · PMID 35504917 · DOI 10.1038/s41392-022-00996-y
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R, Chaudhary JK, Jain N, Chaudhary PK, et al · · 2021 · cited 294× · PMID 33917481 · DOI 10.3390/cells10040821
Coronavirus vaccine development: from SARS and MERS to COVID-19.
Li YD, Chi WY, Su JH, Ferrall L, et al · · 2020 · cited 242× · PMID 33341119 · DOI 10.1186/s12929-020-00695-2

Verify or expand the search:

Other trials of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Trials testing the same drug.

NCT05169008 — A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adoles · Phase 3 · terminated
NCT04840992 — Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation · Phase 1, PHASE2 · completed
NCT04566770 — A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) · Phase 2 · completed
NCT04540419 — Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 · Phase 3 · completed
NCT04398147 — Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada · Phase 1, PHASE2 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other CanSino Biologics Inc. trials

Trials by the same sponsor.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT06708286 — A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) · Phase 2, PHASE3 · active not recruiting
NCT06700148 — A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds · Phase 3 · active not recruiting
NCT06120751 — A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population · Phase 3 · completed
NCT06101173 — A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Health · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04526990 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CanSino Biologics Inc.
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04526990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing